BPC-157: What Published Research Has Examined

A sourced overview of the published BPC-157 literature: what the peptide is, which preclinical models researchers have studied, what reviews say about the evidence, and the open questions that remain.

For laboratory research use only. 21+.

BPC-157 is one of the most searched-for research peptides, and one of the most over-described. Much of what circulates online goes far beyond what the published literature actually shows.

This article sticks to the literature. It covers what BPC-157 is, which experimental models researchers have used, what independent reviewers say about the quality and limits of the evidence, and the questions that remain open. It describes what studies examined. It does not describe what the compound will do, and it gives no guidance on use outside the laboratory.

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide: a chain of 15 amino acids. Its sequence is reported in the literature as GEPPPGKPADDAGLV, with a molecular weight of about 1419 Da (Staresinic et al., 2003). The name comes from "body protection compound." Researchers describe it as a partial sequence of a protein originally isolated from human gastric juice (Chang et al., 2011).

Most research peptides like this are made by solid-phase peptide synthesis and supplied as a freeze-dried powder. For background on how peptide sequences are written and how research peptides are made, see our guide to peptides.

Regulatory status

BPC-157 is not approved by the US Food and Drug Administration. A 2025 literature and patent review states it has not been approved "due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans" (Józwiak et al., 2025). The same review notes that the World Anti-Doping Agency temporarily listed it as banned in 2022.

Where the research comes from

A large share of the published BPC-157 literature comes from a single research group at the University of Zagreb in Croatia, which has published on the peptide since the early 1990s. Independent groups have also contributed, notably a group at Chang Gung University in Taiwan that studied tendon cells. A 2025 systematic review identified 544 articles published from 1993 to 2024. After screening, it included 36 studies: 35 preclinical and 1 clinical (Vasireddi et al., 2025).

That ratio is the most important fact about the BPC-157 evidence base, and the rest of this article should be read with it in mind.

Research area 1: Tendon and ligament models

Tendon research is the most-cited part of the BPC-157 literature.

Achilles tendon (rat). In a 2003 study, researchers surgically transected the Achilles tendon in rats and compared animals given BPC-157 with saline controls over 14 days. They assessed biomechanical, functional, microscopic and macroscopic measures and reported improvements across them in the BPC-157 group. In cell culture, the peptide did not stimulate tendon cell growth on its own, but it counteracted the growth-inhibiting effect of the aldehyde 4-hydroxynonenal (Staresinic et al., 2003; DOI: 10.1016/S0736-0266(03)00110-4).

Tendon fibroblasts (cell and explant studies). The Chang Gung group investigated possible mechanisms. In a 2011 study, BPC-157 did not directly affect tendon fibroblast proliferation. It did increase outgrowth from tendon explants, cell survival under oxidative (H₂O₂) stress, and cell migration and spreading, alongside increased phosphorylation of the FAK and paxillin signaling proteins (Chang et al., 2011; DOI: 10.1152/japplphysiol.00945.2010). A 2014 follow-up used cDNA microarray analysis and reported that growth hormone receptor was among the most strongly up-regulated genes in rat tendon fibroblasts exposed to BPC-157 (Chang et al., 2014; DOI: 10.3390/molecules191119066).

Medial collateral ligament (rat). A 2010 study transected the medial collateral ligament in rats and followed the repair process for up to 90 days, comparing several routes of administration. The authors reported functional, biomechanical, macroscopic and histological differences versus controls (Cerovecki et al., 2010; DOI: 10.1002/jor.21107).

Research area 2: Muscle models

Transected quadriceps (rat). A 2006 study completely transected the quadriceps muscle in rats and followed the animals for 72 days. The authors reported differences in load of failure, walking and motor function indices, and in microscopic measures such as desmin staining and myofibril diameter, compared with controls (Staresinic et al., 2006; DOI: 10.1002/jor.20089).

Blood-vessel formation in muscle and tendon injury models. A 2009 study looked at blood-vessel formation. In cell culture, the researchers found no direct angiogenic effect of BPC-157. In crushed-muscle and transected muscle and tendon models in vivo, they reported increased staining for VEGF, CD34 and FVIII, which they interpreted as modulated angiogenesis linked to the repair process (Brcic et al., 2009).

Research area 3: Gastrointestinal models

Given its origin as a gastric-juice fragment, BPC-157 has been studied extensively in gastrointestinal models, almost entirely in rats and largely by the Zagreb group. A 2011 review by that group summarizes rat studies of lesions induced by alcohol and NSAIDs, esophageal and pyloric sphincter function, intestinal anastomoses and fistulas, and a short-bowel model (Sikiric et al., 2011; DOI: 10.2174/138161211796196954). This area also generated interest in the peptide's interactions with the nitric oxide system.

Readers should note that these reviews are written largely by the group that produced the underlying studies. Independent replication of the gastrointestinal findings is limited.

Research area 4: Pharmacokinetics

For years, one clear gap was basic pharmacokinetic data. A 2022 study from the Air Force Medical University in Xi'an reported the first analysis of BPC-157 pharmacokinetics, distribution, metabolism and excretion in rats and beagle dogs. The authors found an elimination half-life of the intact peptide of under 30 minutes. Using a radiolabeled version, they found it was rapidly broken down into small peptide fragments and amino acids, and excreted mainly via urine and bile (He et al., 2022; DOI: 10.3389/fphar.2022.1026182).

The short half-life raises a mechanistic question that the literature hasn't fully resolved: how much of the reported activity comes from the intact peptide and how much from its fragments?

What independent reviewers say about the evidence

Three recent reviews are worth reading in full because they assess the literature critically rather than summarizing it favorably.

Vasireddi et al., 2025 (systematic review). Of the 36 included studies, 35 were preclinical. The authors classify the evidence as level IV and V, the lowest tiers of clinical evidence. They found no clinical safety data, and they note that adverse effects are possible due to "unregulated manufacturing, contamination, or unknown clinical safety" (Vasireddi et al., 2025; DOI: 10.1177/15563316251355551).

Mayfield et al., 2026 (narrative review). Reviewing BPC-157 alongside other peptides, the authors conclude that tendon and muscle findings are "largely unvalidated in human trials." They describe the single published human case series as having "significant methodological flaws and a lack of controls." They also stress that fundamental parameters remain unknown (Mayfield et al., 2026; DOI: 10.1177/03635465251357593).

Moiz et al., 2026. This review of unregulated peptides lists BPC-157 among compounds that "lack established human safety profiles." It raises concerns including product contamination, manufacturing impurities and inaccurate content, as well as theoretical concerns relating to angiogenesis (Moiz et al., 2026).

Open questions in the literature

Based on the reviews above, the main open questions are:

  1. Human evidence. There are no published randomized controlled trials.
  2. Independent replication. Much of the in vivo work comes from one group.
  3. Mechanism. Proposed pathways include FAK–paxillin signaling, growth hormone receptor expression, VEGF-related angiogenesis and nitric oxide interactions. None is established as primary.
  4. Intact peptide vs. fragments, given the short half-life reported in animals.
  5. Long-term safety, including the theoretical questions reviewers raise about angiogenesis.
  6. Material quality. Reviewers repeatedly flag contamination and manufacturing variability as a confounder. For a lab, that makes lot-level identity and purity data essential.

Why material quality matters for BPC-157 research

The last point is the one a laboratory controls directly. When published reviewers name unregulated manufacturing and contamination as confounders, the quality of the material becomes part of the experimental design. At minimum, a lab should be able to check the lot it received for:

  • identity (LC-MS observed mass consistent with the theoretical mass of about 1419 Da);
  • purity (HPLC, with the chromatogram);
  • endotoxin, especially for cell-based work.

Seratide supplies BPC-157 as lyophilized powder in lot-numbered vials, for laboratory research use only. Each lot has a record on our Lot lookup page in the format above. Today these are clearly labeled layout samples that show the format, not measurements. Issued laboratory reports replace them as lots are analyzed.

Sources

All sources below were opened and checked against their PubMed records while drafting. The full title of each paper is on its PubMed page.

  1. Staresinic M, et al. J Orthop Res. 2003;21(6):976-83. PubMed: https://pubmed.ncbi.nlm.nih.gov/14554208/ · DOI: https://doi.org/10.1016/S0736-0266(03)00110-4
  2. Chang CH, et al. J Appl Physiol. 2011;110(3):774-80. PubMed: https://pubmed.ncbi.nlm.nih.gov/21030672/ · DOI: https://doi.org/10.1152/japplphysiol.00945.2010
  3. Chang CH, et al. Molecules. 2014;19(11):19066-77. PubMed: https://pubmed.ncbi.nlm.nih.gov/25415472/ · DOI: https://doi.org/10.3390/molecules191119066
  4. Cerovecki T, et al. J Orthop Res. 2010;28(9):1155-61. PubMed: https://pubmed.ncbi.nlm.nih.gov/20225319/ · DOI: https://doi.org/10.1002/jor.21107
  5. Staresinic M, et al. J Orthop Res. 2006;24(5):1109-17. PubMed: https://pubmed.ncbi.nlm.nih.gov/16609979/ · DOI: https://doi.org/10.1002/jor.20089
  6. Brcic L, et al. J Physiol Pharmacol. 2009;60 Suppl 7:191-6. PubMed: https://pubmed.ncbi.nlm.nih.gov/20388964/ (no DOI listed in PubMed)
  7. Sikiric P, et al. Curr Pharm Des. 2011;17(16):1612-32. PubMed: https://pubmed.ncbi.nlm.nih.gov/21548867/ · DOI: https://doi.org/10.2174/138161211796196954
  8. He L, et al. Front Pharmacol. 2022;13:1026182. PubMed: https://pubmed.ncbi.nlm.nih.gov/36588717/ · DOI: https://doi.org/10.3389/fphar.2022.1026182
  9. Vasireddi N, et al. HSS J. 2025;21(4):485-495. PubMed: https://pubmed.ncbi.nlm.nih.gov/40756949/ · DOI: https://doi.org/10.1177/15563316251355551
  10. Józwiak M, et al. Pharmaceuticals (Basel). 2025;18(2):185. PubMed: https://pubmed.ncbi.nlm.nih.gov/40005999/ · DOI: https://doi.org/10.3390/ph18020185
  11. Mayfield CK, et al. Am J Sports Med. 2026;54(1):223-229. PubMed: https://pubmed.ncbi.nlm.nih.gov/41476424/ · DOI: https://doi.org/10.1177/03635465251357593
  12. Moiz A, et al. Mo Med. 2026;123(4):337-343. PubMed: https://pubmed.ncbi.nlm.nih.gov/42757290/ (no DOI listed in PubMed)

For laboratory research use only.

More from the library